The Full Wiki

More info on Ro48-6791

Ro48-6791: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Ro48-6791
Systematic (IUPAC) name
3-{5-[(dipropylamino)methyl]- 1,2,4-oxadiazol-3-yl}- 8-fluoro- 5-methyl- 4,5-dihydro- 6H-imidazo[1,5-a] [1,4]benzodiazepin- 6-one
Identifiers
CAS number  ?
ATC code  ?
PubChem 9953485
Chemical data
Formula C 21H25FN6O2  
Mol. mass 412.47
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Ro48-6791 is a drug, a benzodiazepine derivative developed by Hoffman-LaRoche in the 1990s.

Ro48-6791 was developed as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Ro48-6791 has properties similar to those of to midazolam, being water soluble, with a fast onset and short duration of action. It is 4-6x more potent than midazolam,[1] and slightly shorter acting,[2] and produces similar side effects such as sedation and amnesia.

It was tested up to Phase II human trials, but while it produced less respiratory depression than propofol, it had a longer recovery time and was deemed not to have any significant advantages over the older drug.[3] Similarly when Ro48-6791 was compared to midazolam, it had similar efficacy, higher potency and a shorter recovery time, but produced less of a synergistic effect on opioid-induced analgesia and produced more severe side effects such as dizziness after the procedure.[4] Consequently it was dropped from clinical development,[5] although it is still used in scientific research.[6]

See also

References

  1. ^ Dingemanse, J; Van Gerven; Schoemaker; Roncari; Oberyé; Van Oostenbruggen; Massarella; Segala et al. (1997). "Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects". British journal of clinical pharmacology 44 (5): 477–86. doi:10.1046/j.1365-2125.1997.t01-1-00612.x. PMID 9384465.  
  2. ^ Hering, W; Ihmsen; Albrecht; Schwilden; Schüttler (1996). "Ro 48-6791 – ein kurzwirksames Benzodiazepin Untersuchungen zur Pharmakokinetik und Pharmakodynamik bei jungen und älteren Probanden im Vergleich mit Midazolam [RO 48-6791--a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam]" (in German). Der Anaesthesist 45 (12): 1211–4. doi:10.1007/s001010050360. PMID 9065257.  
  3. ^ Wrigley, PJ; Elliott; Blake (1998). "A phase 2 clinical trial comparing Ro 48-6791, a new short-acting benzodiazepine, with propofol for induction of anaesthesia". Anaesthesia and intensive care 26 (5): 509–14. PMID 9807605.  
  4. ^ Tang, J; Wang; White; Gold; Gold (1999). "Comparison of the sedation and recovery profiles of Ro 48-6791, a new benzodiazepine, and midazolam in combination with meperidine for outpatient endoscopic procedures". Anesthesia and analgesia 89 (4): 893–8. doi:10.1097/00000539-199910000-00014. PMID 10512261.  
  5. ^ Gold, ME; Todd; Spiegler; Gold (1999). "When the drug trial fails: an approach to clinical drug studies". AANA journal 67 (6): 505–12. PMID 10876442.  
  6. ^ Ihmsen, H; Albrecht; Hering; Schüttler; Schwilden (2004). "Modelling acute tolerance to the EEG effect of two benzodiazepines". British journal of clinical pharmacology 57 (2): 153–61. doi:10.1046/j.1365-2125.2003.01964.x. PMID 14748814.  
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message